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Abstract
Radiation-attenuated Plasmodium sporozoites (RAS) are the only vaccine shown to induce sterilizing protection against
malaria in both humans and rodents. Importantly, these ‘‘whole-parasite’’ vaccines are currently under evaluation in
human clinical trials. Studies with inbred mice reveal that RAS-induced CD8 T cells targeting liver-stage parasites are
critical for protection. However, the paucity of defined T cell epitopes for these parasites has precluded precise
understanding of the specific characteristics of RAS-induced protective CD8 T cell responses. Thus, it is not known
whether quantitative or qualitative differences in RAS-induced CD8 T cell responses underlie the relative resistance or
susceptibility of immune inbred mice to sporozoite challenge. Moreover, whether extraordinarily large CD8 T cell
responses are generated and required for protection following RAS immunization, as has been described for CD8 T cell
responses following single-antigen subunit vaccination, remains unknown. Here, we used surrogate T cell activation
markers to identify and track whole-parasite, RAS-vaccine-induced effector and memory CD8 T cell responses. Our data
show that the differential susceptibility of RAS-immune inbred mouse strains to Plasmodium berghei or P. yoelii sporozoite
challenge does not result from host- or parasite-specific decreases in the CD8 T cell response. Moreover, the surrogate
activation marker approach allowed us for the first time to evaluate CD8 T cell responses and protective immunity
following RAS-immunization in outbred hosts. Importantly, we show that compared to a protective subunit vaccine that
elicits a CD8 T cell response to a single epitope, diversifying the targeted antigens through whole-parasite RAS
immunization only minimally, if at all, reduced the numerical requirements for memory CD8 T cell-mediated protection.
Thus, our studies reveal that extremely high frequencies of RAS-induced memory CD8 T cells are required, but may not
suffice, for sterilizing anti-Plasmodial immunity. These data provide new insights into protective CD8 T cell responses
elicited by RAS-immunization in genetically diverse hosts, information with relevance to developing attenuated whole-
parasite vaccines.
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Introduction
Plasmodium infections are a global health crisis resulting in ,300
million cases of malaria each year and ,1 million deaths
[1,2,3,4,5]. At present, there are no effective licensed anti-malarial
vaccines. Most vaccines under clinical evaluation are only partially
protective and, for unknown reasons, immunity rapidly wanes [6].
Thus, development of an effective malaria vaccine that provides
long-term protection remains an important goal to improve global
health.
Immunization with radiation-attenuated sporozoites (RAS) is
the only documented means to induce sterilizing protection in
both humans [7,8] and rodents [9] and, importantly this approach
is under evaluation in clinical trials [10]. Studies with inbred
mouse strains reveal a prominent and often essential role for CD8
T cells in RAS-induced protection [11]. However, RAS-immune
inbred mice also exhibit substantial differences in resistance to
challenge with Plasmodium berghei (Pb) or P. yoelii (Py) sporozoites,
two major models of experimental malaria that are thought to
differ in virulence. Despite decades of research, the precise
characteristics of protective memory CD8 T responses following
RAS-vaccination remain poorly understood. One reason for this
relates to the limited number of defined CD8 T cell epitopes
derived from rodent species of Plasmodia.
BALB/c mice mount H-2K
d-restricted CD8 T cell responses
against single defined circumsporozoite (CS) protein-derived
epitopes from either Pb or Py and these epitopes can be targets
of protective CD8 T cells [12,13]. However, despite evidence that
non-CS antigens can also be targets of protective immunity
[14,15], there are few additional Plasmodium-specific epitopes
identified from antigens other than CS in BALB/c mice, and no
identified protective epitopes in H-2
b C57BL/6 (B6) mice. Thus,
PLoS Pathogens | www.plospathogens.org 1 July 2010 | Volume 6 | Issue 7 | e1000998the paucity of epitope information for these parasites has
contributed to our incomplete understanding of the specific
quantitative and qualitative characteristics of RAS-induced CD8
T cell responses in inbred mice that are relatively easy (BALB/c)
or difficult (B6) to protect against Plasmodium sporozoite challenge
[11]. Moreover, we recently showed that the threshold of memory
CD8 T cell responses to the Pb-CS epitope (monospecific
responses) required for sterilizing immunity against sporozoite
challenge was extremely large [16]. Importantly, it is unknown
whether a more diverse memory CD8 T cell response generated
by whole parasite based RAS vaccination will decrease the
threshold number of memory cells required for protection. This
issue is of great relevance to translation of the attenuated whole
parasite vaccines to humans.
The identification and characterization of infection- or
vaccination-induced, antigen-specific CD8 T cell populations
has historically required defined antigenic peptide determinants
with known MHC restriction. However, specific activation
markers can be used to track effector, but not memory, CD8
T cell responses to viral vaccines in humans in the absence of
defined antigenic determinants or known MHC-restriction [17].
We recently described an alternative surrogate actiation marker
approach, relying on concurrent downregulation of surface
CD8a and upregulation of CD11a (a-chain of LFA-1) on effector
and memory antigen-specific CD8 T cells responding to
bacterial and viral-infections in mice [18]. Herein, we apply
this surrogate marker approach to identify and longitudinally
track the total CD8 T cell response following RAS-immunization
in rodents. This surrogate marker approach allowed us for the
first time to evaluate CD8 T cell responses and protective
immunity to RAS-immunization in both inbred and outbred
hosts. Collectively, our data show that despite broadening the
number of antigenic targets through whole-parasite vaccination,
extraordinarily large numbers of memory CD8 T cells are
required, but not always sufficient, to protect the host against
liver-stage Plasmodium infection. These data provide fundamen-
tally new insight into protective CD8 T cell responses elicited by
RAS-immunization in genetically diverse hosts, information with
relevance to developing attenuated whole-parasite vaccines to
protect humans.
Results
The CD8a
loCD11a
hi T cell phenotype specifically
identifies RAS vaccine-induced effector and memory CD8
T cells
Relative resistance after RAS-vaccination of both rodents and
humans is commonly studied by sporozoite challenge 1–2 weeks
following the last immunization [8,11,19,20] and thus evaluates
immunity mediated by recently stimulated T cell populations.
Herein, we wished to examine RAS-induced protection only
after stable memory immune responses have been generated.
Thus, we challenged RAS-vaccinated mice .60 days post-
immunization, when numerically and phenotypically stable
memory CD8 T cell populations are established following acute
infections [21]. At this memory time point, a single Pb-RAS
vaccination protected 100% of BALB/c mice, but failed to
protect any B6 mice against homologous Pb sporozoite
challenge, whereas one Py-RAS vaccination had minimal
(BALB/c, 10%) or no (B6, 0%) protective efficacy against
homologous Py sporozoite challenge (Figure 1A). These data
demonstrate both mouse strain and Plasmodium species-depen-
dent protection after single RAS-immunization of mice
c h a l l e n g e da tab o n af i d em e m o r yt i m ep o i n t .
To examine the protective CD8 T cell response elicited by
RAS-vaccination, we applied our recently described surrogate
activation marker approach, based on downregulation of CD8a
and upregulation of CD11a (CD8a
loCD11a
hi) [18], to identify
RAS-induced CD8 T cells. We chose to focus our initial analyses
on peripheral blood (PBL) so that individual mice could be
analyzed longitudinally. Importantly, long-term longitudinal
analyses of naı ¨ve mice in our colony reveal that the circulating
CD8a
loCD11a
hi T cell pool remains low (2–3% of all circulating
CD8 T cells) and stable for .250 days (data not shown). For
vaccinated mice, the fraction of CD8a
loCD11a
hi T cells in the
PBL was determined prior to, and at various intervals after,
immunization with 2610
4 Pb-RAS in individual animals. We
detected substantial increases in the frequency of CD8a
loCD11a
hi
T cells in the blood of vaccinated mice at 7 and 61 days (effector
and memory time points, respectively) post-immunization
(Figure 1B, left column as an example). Interestingly, only
1663% of Pb-RAS-induced effector (day 7) CD8 T cells in BALB/
c mice are specific for the known H-2K
d-restricted CS252–260
epitope and, importantly, all of these defined antigen-specific CD8
T cells are found in the CD8a
loCD11a
hi population (Figure 1B,
right columns). Moreover, the fraction of CS252–260-specific
CD8 T cells among the CD8a
loCD11a
hi population consistently
remains ,16% throughout the memory phase of the response (day
61) (Figure 1B, right columns). Based on previous studies
showing that T cell responses against diverse epitopes are
coordinately regulated [22], these data further support that the
surrogate activation marker approach identifies true RAS-
induced, Plasmodium-specific CD8 T cells. Thus, ,85% of Pb-
RAS-induced CD8 T cells in BALB/c mice are reactive against
epitopes from undefined antigens. Similar results were obtained
for the CS280–288 epitope after single immunization of BALB/c
mice with Py-RAS, although the fraction of CS280–288-specific
memory CD8 T cells in the circulating CD8a
loCD11a
hi
compartment was only ,7% (data not shown).
To further demonstrate specificity of the surrogate activation
marker approach, we determined that the increase over baseline
(PBL analyzed before immunization) in the fraction of circulating
CD8a
loCD11a
hi T cells 5–7 days after immunization depended on
the immunizing dose of Pb-RAS in both BALB/c and B6 mice
(Figure 1C and E) and was not observed in mice immunized
Author Summary
Plasmodium infections are a global health crisis resulting in
,300 million cases of malaria each year and ,1 million
deaths. Radiation-attenuated Plasmodium sporozoites
(RAS) are the only vaccines that induce sterilizing anti-
malarial immunity in humans. Importantly, ‘‘whole para-
site’’ anti-malarial RAS vaccines are currently under
evaluation in clinical trials. In rodents, RAS-induced
protection is largely mediated by CD8 T cells. However,
the quantitative and qualitative characteristics of RAS-
induced protective CD8 T cell responses are unknown.
Here, we used surrogate markers of T cell activation to
reveal the magnitude and kinetics of Plasmodium-specific
CD8 T cell responses following RAS-immunization in both
inbred and outbred mice. Our data show that, indepen-
dent of host genetic background, extremely large memory
CD8 T cell responses were required, but not always
sufficient for sterilizing protection. These data have broad
implications for evaluating total T cell responses to
attenuated pathogen-vaccines and direct relevance for
efforts to translate attenuated whole-Plasmodium vaccines
to humans.
Plasmodium-Induced Total Memory CD8 T Cell Responses
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loCD11a
hi surrogate activation marker approach to identify RAS vaccination-
induced CD8 T cell responses. (A) Protection against P. berghei (Pb)o rP. yoelii (Py) sporozoite challenge in BALB/c and B6 mice singly vaccinated
with either 2610
4 Pb-o rPy-RAS and challenged with 1000 Pb or Py sporozoites .80 days later. Numbers indicate % protected (no. protected/no.
challenged6100). (B) Peripheral blood mononuclear cells from a single BALB/c mouse collected before (day 0) and after 2610
4 Pb-RAS vaccination
(day 7, 61) were stained for CD8a and CD11a. Left column of dot plots shows the fraction of circulating CD8 T cells exhibiting an antigen-experienced
phenotype (CD8a
loCD11a
hi) at each time point following Pb-RAS vaccination. Right columns of dot plots show the fraction of cells within the CD11a
hi
and CD11a
lo gates that stain with K
d/CS252–260 tetramer. (C) BALB/c mice were vaccinated with the indicated number of Pb-RAS and CD8a
loCD11a
hi
responses were tracked in the peripheral blood of individual mice on day 0, 5, 6 and 7. N=10 mice/dose, except for 1610
5 Pb-RAS group (N=5). Data
are the mean 6 S.D. (D) Irradiated salivary gland homogenate from non-infected mosquitoes was injected into naı ¨ve BALB/c mice i.v. The
CD8a
loCD11a
hi response was evaluated in the peripheral blood of individual mice before (day 0) and after (day 6) injection. ‘Equivalent’ refers to the
final dilution of salivary gland homogenate injected into mice within each group. Dilutions were made based on an average recovery of ,15,000
sporozoites per mosquito, calculated over .15 independent mosquito dissections. Data are mean 6 S.D. for 3 mice per group. (E,F) similar to C,D
except C57BL/6 mice were analyzed.
doi:10.1371/journal.ppat.1000998.g001
Plasmodium-Induced Total Memory CD8 T Cell Responses
PLoS Pathogens | www.plospathogens.org 3 July 2010 | Volume 6 | Issue 7 | e1000998with an equivalent suspension of irradiated salivary gland
homogenates from non-infected mosquitoes (Figure 1D and F).
Thus, the CD8a
loCD11a
hi T cell response is specific for
Plasmodium-antigens and not mosquito salivary gland antigens.
Moreover, CD8 T cell responses in the blood of RAS-immune B6
and BALB/c mice were representative of CD8a
loCD11a
hi
responses in the spleen and liver, both in terms of frequency
(Figure 2A) and total number (Figure 2B). Finally, we addressed
specificity at the memory stage by transferring sort purified
CD8a
hiCD11a
lo (naı ¨ve) or CD8a
loCD11a
hi (memory) cells from
day 78 RAS-immune B6 mice (CD45.2) into CD45.1 hosts. Only
the population of transferred CD8a
loCD11a
hi T cells underwent
secondary expansion after RAS-immunization of the recipient
mice (Figure S1). Thus, the CD8a
loCD11a
hi phenotype cells
present at memory time points after RAS-immunization are
Plasmodium-specific (Figure S1). As a composite, these data
demonstrate that the changes in frequency of circulating
CD8a
loCD11a
hi T cells in individual RAS-immunized mice
reflects the distribution of parasite-specific effector and memory
CD8 T cells in peripheral tissues and can be used to evaluate the
total CD8 T cell response to RAS-immunization prior to
sporozoite challenge.
Longitudinal analyses of RAS-induced effector and
memory CD8 T cell responses
We next examined the magnitude and kinetics of total CD8 T
cell responses in the PBL of BALB/c and B6 mice following Pb-o r
Py-RAS vaccination (Figure 3A and B, respectively), using an
immunizing dose of RAS (2610
4 sporozoites) that fell within the
linear range of the CD8 T cell response in both inbred mouse
strains (Figure 1C,E). We observed substantial increases in the
frequency of CD8a
loCD11a
hi T cells in the PBL of all groups,
which peaked 6 days after RAS-immunization, followed by
contraction and the formation of numerically stable primary (1u)
memory populations (Figure 3A,B). Importantly, although B6
mice are more susceptible to sporozoite challenge following a
single Pb-o rPy-RAS immunization compared to BALB/c mice
[11] (Figure 1A), and CD8 T cells are necessary to mediate
protection in Pb-RAS immune mice (Figure 3C), Pb-o rPy-RAS
vaccination of B6 mice induced 1u effector and memory CD8 T
cell responses that were ,2-fold higher (p,0.0001) than observed
in BALB/c mice (Figure 3A,B). Thus, our surrogate activation
marker approach revealed that the susceptibility of single RAS-
immunized B6 mice to homologous Pb or Py challenge is not due
to a diminished total anti-Plasmodial CD8 T cell response.
Figure 2. RAS vaccination of BALB/c and C57BL/6 mice increases the frequency and total number of CD8a
loCD11a
hi cells in spleen,
liver and peripheral blood. Naı ¨ve BALB/c and C57BL/6 mice were vaccinated with 2610
4 Py-RAS. Seven days later, mononuclear cells were
isolated from the spleen, liver and blood of immune (N=3/group) and naı ¨ve (N=3) mice and stained for CD8a and CD11a. Data (mean 6 S.D.) are
expressed as the frequency (A) or total number (B) of CD8 T cells exhibiting the antigen-experienced phenotype (CD8a
loCD11a
hi) in each tissue.
Statistics were determined by unpaired, two-tailed t-tests.
doi:10.1371/journal.ppat.1000998.g002
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undergo differentiation into blood stage merozoites [23,24].
Interestingly, persistence (up to 6 months) of radiation-attenuated
parasites was reported in the livers of RAS-vaccinated rats [25]
and persistence of attenuated parasites has been hypothesized to
underlie the long-term protective capacity of RAS-induced
memory CD8 T cells [25,26]. To address this hypothesis, we
treated BALB/c mice with 60 mg/kg primaquine on days 5 and 6
following Pb-RAS-vaccination to eliminate persisting parasites. In
contrast to previous studies [25,26], we found that primaquine
treatment did not decrease protection against sporozoite challenge
at a memory time point (Figure 3E). Consistent with this result,
primaquine treatment at these time points did not reduce RAS-
specific circulating CD8 T cell frequencies (Figure 3D,E). In
parallel, we verified the efficacy of primaquine (route, dose,
schedule) by treating naive BALB/c mice 24 and 48 hrs following
Figure 3. The magnitude and kinetics of RAS-vaccination-induced CD8 T cell responses in BALB/c and C57BL/6 inbred mice. (A and
B) Kinetics and magnitude of the total CD8 T cell response in the blood of BALB/c and C57BL/6 mice following 2610
4 Pb-RAS (A)o rPy-RAS (B)
vaccination. Data (mean6S.D.) are from 30 mice/strain. *P,0.0001, **P,0.0001. (C) BALB/c mice (N=20) were vaccinated with 2610
4 Pb-RAS. Ninety-
six days later, the frequency of CD8a
loCD11a
hi T cells in the peripheral blood was evaluated and individual mice were ranked according to the
magnitude of the memory CD8 T cell response. Mice were treated with rat IgG, anti-CD4 (GK1.5) or anti-CD8 (2.43) 3 days and 1 day prior to challenge
with 1000 Pb sporozoites. Numbers above refer to percent of T cell-depleted mice protected (no. protected/no. challenged 6100) following
sporozoite challenge. (D) BALB/c mice were vaccinated with 2610
4 Pb-RAS. On days 5 and 6 post-vaccination, mice were injected i.p. with PBS or
60 mg/kg primaquine/PBS solution (arrows). Circulating CD8 T cell responses were evaluated in mice at the indicated time points. (E) Fifty-six days
following Pb-RAS vaccination, CD8 T cell responses in the blood were evaluated. Mice were challenged 3 days later (day 59) with 1000 Pb sporozoites.
Numbers refer to % protected (no. protected/no. challenged6100). Data in D,E are mean6S.D. from 8–10 mice/group. Statistics in A, B and E were
determined by unpaired, two-tailed t-tests.
doi:10.1371/journal.ppat.1000998.g003
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effectively stopped the development of blood stage infection in
100% (5/5) mice, whereas 5/5 vehicle-treated mice developed
patent blood stage parasitemia. Thus, following the induction of
CD8 T cell responses via Pb-RAS-vaccination of BALB/c mice,
the persistence of attenuated parasites in the liver does not regulate
the stability or protective capacity of the RAS-induced memory
CD8 T cell populations.
Homologous boosting markedly expands RAS-induced
memory CD8 T cell populations but fails to confer
protective immunity to C57BL/6 mice
Short-interval (every 2–3 weeks) booster RAS-immunizations
improve protection against sporozoite challenge of mice
[11,27,28] although the impact on the Plasmodium-specific CD8
T cell compartment is unknown. Additionally, the impact of long-
interval boosting, as generally employed in human vaccines, on
RAS-induced protection at a secondary memory time point is
unknown. Thus, we examined the effect of homologous RAS-
boosting on bona fide memory CD8 T cell populations. Booster
immunization at memory time points (60–80 days after initial
priming) with Pb-RAS in B6 mice or Py-RAS in BALB/c mice
induced secondary expansion of CD8a
loCD11a
hi T cells
(Figure 4A,C). Surprisingly, the peak secondary response did
not exceed the magnitude of the peak primary response to initial
priming. Still, booster immunization resulted in a doubling of the
secondary (2u) memory CD8 T cell populations in both mouse
strains (Figure 4B,D). Importantly, we observed 100% protection
in Pb-RAS-vaccinated B6 mice and Py-RAS-vaccinated BALB/c
mice following sporozoite challenge at 2u memory time points after
boosting (days 168 and 154, respectively) (Figure 4B,D), which
remained wholly CD8 T cell-dependent (Figure S2). Of note,
homologous Pb-o rPy-RAS-boosting enriched the fraction of
CS252–260-o rC S 280–288-specific CD8 T cells (to ,30% and 15%,
respectively) within the CD8a
loCD11a
hi compartment compared
to single immunized BALB/c mice (Figure 1B and Figure S3).
Importantly, these secondary CS252–260-o rC S 280–288-specific
memory CD8 T cells are also found exclusively in the
CD8a
loCD11a
hi compartment (Figure S3). Thus, homologous
Pb-RAS or Py-RAS boosting of B6 or BALB/c mice, respectively,
doubles the frequency of circulating RAS-specific 2u memory CD8
T cells and affords CD8 T cell-dependent sterilizing immunity
Figure 4. Homologous Pb-o rPy-RAS boosting of mice elicits robust memory CD8 T cell responses but does not enhance protection
of C57BL/6 mice against Py sporozoite challenge. (A) The kinetics and magnitude of the circulating RAS vaccine-induced CD8 T cell response in
C57BL/6 mice primed and boosted (arrows) with 2610
4 Pb-RAS. (B) Fold increase in secondary memory (d168) CD8 T cell responses in the blood of
C57BL/6 mice following homologous Pb-RAS boost. Numbers to the right indicate the fraction of primary (1u) or secondary (2u) memory C57BL/6 mice
that were protected following Pb sporozoite challenge (no. protected/no. challenged 6100). (C,D) Similar to A,B, except BALB/c mice were prime-
boosted (arrows) with 2610
4 Py-RAS and challenged with P. yoelii sportozoites. Data in A–D are mean6S.D. from 20 mice. (E,F) Similar to C,D, except
C57BL/6 mice were primed and boosted twice (arrows) with 2610
4 Py-RAS. Data in E,F are mean6S.D. from 30 mice. Statistics were determined by
unpaired, two-tailed t-tests. For B,D and F, one hundred percent (10/10) of strain- and age-matched, naı ¨ve mice challenged in parallel were
parasitized.
doi:10.1371/journal.ppat.1000998.g004
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the CS-specific responses in RAS-boosted BALB/c mice suggests
that although ,85–95% of the total initial CD8 T cell response
targets antigens of undefined specificity, the CS-specific response
in BALB/c mice dominates the recall response. These data for the
first time reveal the effect of homologous RAS boosting on bona
fide memory CD8 T cell responses, and further demonstrate that
antigen-specific 2u memory CD8 T cell populations are also
accurately identified using the CD8a
loCD11a
hi surrogate activa-
tion marker approach.
Consistent with the results described above, homologous
boosting of Py-RAS immune B6 mice also doubled (on average)
the frequency of RAS-induced 2u memory CD8 T cells
(Figure 4E,F). However, these mice exhibited only modest
(40%) protection against sporozoite challenge at a 2u memory time
point (day 154) (Figure 4F). Interestingly, a second booster
immunization with Py-RAS resulted in a sustained increase in the
frequency of CD8a
loCD11a
hi T cells, which now represented on
average ,40% of the CD8 T cell compartment of the PBL at day
215 (Figure 4E,F). However, even this extreme commitment of
Py-RAS-induced tertiary (3u) memory CD8 T cells did not
improve protection when these mice were challenged at a 3u
memory time point (day 215) (Figure 4F). Thus, we could not
achieve substantial levels (.70–80%) of protection against Py
sporozoite challenge in B6 mice boosted every 60–70 days and
challenged 60 days after the last boost. This contrasts sharply with
reports that examine protective immunity following short interval
boosting (every 2–3 weeks) followed by challenge ,14 days after
the last boost [11,29]. One clear difference between these two
immunization regimens is the substantial role for CD4 T cells in
protection after short-interval boost and challenge approaches in
B6 mice [11,29], whereas we could detect no role for CD4 T cells
in protection against Pb sporozoite challenge of B6 mice, or against
Py challenge of BALB/c mice in our long-interval prime-boost
approach (Figure S2). These disparate results strongly suggest
that the timing of RAS-immunization and sporozoite challenge
significantly influences both the composition and protective
capacity of the RAS-induced cellular response. Indeed, we are
currently evaluating quantitative and qualitative characteristics of
the total CD8 T cell response and protection following short-
interval, prime-boost RAS vaccination and challenge, as well as
evaluating surrogate activation marker approaches to specifically
identify antigen-experienced CD4 T cells.
Longitudinal analyses of RAS vaccine-induced CD8 T cell
responses within individuals of an outbred population
We show that BALB/c and B6 mice fall on opposite ends of the
spectrum regarding their ability to resist sporozoite challenges at
memory time points following either Pb-o rPy-RAS long-
interval prime-boost vaccination. Indeed, many studies [14,30,
31,32,33,34,35,36,37] employ BALB/c mice to evaluate whole-
attenuated parasite vaccine-induced protective immunity, and it is
unclear how these data model CD8 T cell responsiveness and
protective immunity in outbred populations, such as humans,
following RAS-vaccination. Thus, we next turned our attention
toward analyses of the CD8 T cell response in outbred Swiss
Webster mice. Due to the lack of information on MHC alleles and
antigens in outbred populations, this analysis was only made
possible through development of the CD8a
loCD11a
hi surrogate
activation marker approach [18]. On the population level (N=30
mice), the kinetics and magnitude of Py-RAS-induced CD8 T cell
responses of outbred mice mirrored those observed in inbred mice
(Figure 5A). However, and in striking contrast to the inbred mice,
the initial CD8 T cell response following Py-RAS-vaccination in
outbred mice was not uniform and varied widely, both in
magnitude and day of the peak (Figure 5C–F). Consistent with
this, outbred mice also exhibited more variability in the magnitude
of the 1u memory (Figure 5G) and 2u memory (Figure 5H) CD8
T cell response, compared to inbred mice. Similar to what was
observed in both BALB/c and B6 mice singly vaccinated with Py-
RAS, Swiss Webster mice challenged with Py sporozoites at a 1u
memory time point (day 79) were not efficiently protected
(Figure 5B). However, boosting Swiss Webster mice with Py-
RAS resulted in a doubling (on average) of sporozoite-specific 2u
memory CD8 T cells, and 80% of these mice were protected
against a sporozoite challenge on day 154 (Figure 5B). Thus,
CD8a
loCD11a
hi surrogate markers can be used to identify and
longitudinally track protective CD8 T cell responses in outbred
mice following RAS prime-boost vaccination. In addition, these
data show that despite the variability in magnitude of initial RAS-
induced CD8 T cell response of outbred hosts, homologous
boosting increases the secondary memory CD8 T cell population
and protective immunity against sporozoite challenge.
An effector memory (TEM) CD8 T cell phenotype, but not
anti-sporozoite antibody titers, correlates with protective
immunity following Py-RAS vaccination of inbred and
outbred mice
While protection of RAS-vaccinated mice using the long-
interval (.60 days), prime-boost scenario described above is CD8
T cell dependent (Figure S2), RAS-immunization also elicits a
strong sporozoite-specific antibody response [29,38]. To deter-
mine whether differences in the Py-RAS-induced sporozoite-
specific antibody response correlated with relative resistance or
susceptibility to Py sporozoite challenge, we analyzed serum from
individual BALB/c, B6 and Swiss Webster mice for sporozoite-
specific IgG titers at each memory time-point. Importantly, an
examination of anti-sporozoite titers at the secondary memory
time point (day 154), where significant protection was achieved in
BALB/c and Swiss Webster but not B6 mice (Figures 4D and
5B, respectively), revealed no clear correlation between IgG
titers and protection from sporozoite challenge (Figure S4A).
Moreover, antibody titer was not significantly different between 2u
memory BALB/c mice (100% protected) and 3u memory B6 mice
(20% protected) (P=0.0789, Figure S4B), or between individual
protected and non-protected B6 mice (P=0.4484, Figure S4C).
Thus, reduced anti-sporozoite IgG antibody titers do not appear to
explain the enhanced susceptibility of RAS-vaccinated B6 mice to
sporozoite challenge.
We next examined potential qualitative differences in pheno-
type and specific functional attributes of protective and non-
protective memory CD8 T cells. The nature of our longitudinal
analyses precluded the collection of large quantities of blood from
individual immunized mice. Thus, the small clinical sample
limited our initial analyses to a key subset of markers that
distinguish ‘‘central memory’’ (TCM; CD62L
hi, CD27
hi) from
‘‘effector memory’’ (TEM; CD62L
lo, CD27
lo) CD8 T cell
populations [39,40], and a marker associated with memory CD8
T cell survival (IL7 receptor a chain, CD127) [41]. At 60 days
post-immunization most RAS-induced memory CD8 T cells in
each mouse strain, vaccinated with either Pb-o rPy-RAS,
expressed a TEM phenotype (CD62L
lo, CD27
lo, CD127
lo, data
not shown). However, to more directly address potential
relationships between RAS-induced memory CD8 T cell pheno-
type and protection we evaluated expression of the same markers
after Py-RAS boosting of BALB/c and Swiss Webster mice (both
protected) and B6 mice (not protected). The most striking
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mice and protective memory CD8 T cells in BALB/c and Swiss
Webster mice was the differential expression of CD62L
(Figure 6A). Forty percent (on average) of Py-RAS-induced 2u
memory cells in B6 mice expressed the CD62L
hi TCM phenotype
(Figure 6A). In contrast, representation of the CD62L
hi TCM
phenotype among Py-RAS-induced 2u memory cells in BALB/c
and Swiss Webster mice was reduced 3-fold or 4-fold, respectively
(Figure 6A). A similar trend was observed for the CD27
hi
phenotype (Figure 6B), while no correlation between CD127
Figure 5. Py-RAS-specific CD8 T cell responses and protective immunity are markedly enhanced following prime-boost vaccination
of an outbred mouse population. (A) The kinetics and magnitude of CD8 T cell responses in the blood of individual Swiss Webster mice following
priming and boosting (arrows) with 2610
4 Py-RAS. (B) Fold expansion of Py-RAS-induced primary (1u, d79) and secondary (2u, d154) memory CD8 T
cell responses in the blood of Swiss Webster mice. Numbers to the right indicate the fraction of 1u or 2u memory Swiss Webster mice that were
protected following Py sporozoite challenge (no. protected/no. challenged6100). One hundred percent (10/10) of age-matched, naı ¨ve Swiss Webster
mice challenged in parallel were parasitized. Data in B are mean6S.D. from 20 mice. Statistics were determined by unpaired, two-tailed t-tests. BALB/
c( C), C57BL/6 (D) and Swiss Webster mice (E) (N=30 each) were vaccinated with 2610
4 Py-RAS. Peripheral blood was collected before (day 0) and on
days 5–8 following vaccination. CD8a
loCD11a
hi T cell responses were measured in individual BALB/c, C57BL/6 and Swiss Webster mice at the initial
effector stage (F), primary memory (G) or secondary memory (H) following priming and homologous boost with 2610
4 Py-RAS as in A. Each symbol
represents an individual mouse. Numbers in F-H refer to the fold difference between the highest and lowest responders within each mouse strain at
each time point.
doi:10.1371/journal.ppat.1000998.g005
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Thus, non-protective 2u memory CD8 T cells in Py-RAS boosted
B6 mice exhibit a more TCM phenotype, expressing significantly
higher levels of CD62L and CD27 relative to protective 2u
memory CD8 T cells in BALB/c or Swiss Webster mice
(Figure 6A,B).
As a complimentary approach, we next performed a series of
adoptive transfer studies in order to more clearly identify and
directly compare RAS-induced 2u memory CD8 T cells in BALB/
c and B6 mice. We transferred 8610
4 Py-RAS-induced,
CD8a
loCD11a
hi 1u memory (d78) CD8 T cells into allelically
disparate BALB/c and B6 recipients, which were subsequently
immunized with Py-RAS to generate populations of endogenous 1u
memory and allelically marked 2u memory parasite-specific CD8
T cells. One month after the booster immunization, we performed
extensive phenotypic and functional analyses of the donor-derived,
2u memory CD8 T cells in each B6 and BALB/c recipient mouse.
Surface expression of many markers, such as CD25, CD69,
CD43
glyco (Figure 6D and Figure S5) were indistinguishable
between these populations. In addition, we found no statistically
Figure 6. Protection correlates with an effector memory (TEM) phenotype on circulating Py-RAS-induced secondary memory CD8 T
cells in inbred and outbred mice. (A–C) C57BL/6, BALB/c and Swiss Webster mice (N=10/strain) were vaccinated with 2610
4 Py-RAS. Seventy-
nine days later, mice received a homologous boost of 2610
4 Py-RAS. Seventy-five days after boost (day 154), circulating T cells were stained for CD8a,
CD11a, CD62L, CD27 and CD127. (D–F) Py-RAS-specific, secondary memory BALB/c and C57BL/6 CD8 T cells were generated following adoptive
transfer as described in Materials and Methods. (D) Donor-derived cells were analyzed directly ex vivo for surface expression of the indicated
activation- or survival-associated marker. (E) Cells were stimulated ex vivo for 5 hrs using titrations of plate-bound anti-CD3e and subsequently
analyzed for the intracellular expression of granzyme B. Representative dot plots and histograms (top) and summary graph (bottom) are shown. (F)
Cells were stimulated with 1mg/mL plate-bound anti-CD3e for 5.5 hrs prior to staining for intracellular co-expression of IFN-c, TNF-a and IL-2. In A–D,
data represent the fraction of CD8a
loCD11a
hi T cells within each group expressing the indicated marker. Statistics were determined by unpaired, two-
tailed t-tests. Data in D–F are mean6S.D. and represent analyses from 5 individual BALB/c and B6 recipient mice.
doi:10.1371/journal.ppat.1000998.g006
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aE, a4, a5 or a6) or inhibitory receptors (PD-1, LAG-3, 2B4,
CD160, KLRG-1 or CTLA-4) on RAS-induced, 2u memory CD8
T cells in B6 and BALB/c mice (data not shown). However, in line
with our initial observations, RAS-induced, non-protective 2u
memory CD8 T cells in B6 mice exhibit a more TCM-like
phenotype, relative to BALB/c mice, characterized by relatively
higher proportions of CD27 and CD62L expressing cells
(Figure 6D and Figure S5). We also observed significantly
higher CD122 and CD127 expression on RAS-induced, 2u
memory CD8 T cells in B6 mice (Figure 6D and Figure S5).
Collectively, our phenotypic analyses support the notion that a
TEM phenotype among RAS-induced, parasite-specific CD8 T
cells strongly correlates with protection against liver stage
Plasmodium infection.
To examine specific functional attributes of RAS-induced
memory CD8 T cells in BALB/c and B6 mice we relied on
polyclonal TCR cross-linking to trigger the ex vivo induction of
Granzyme B and inflammatory cytokine expression by allelically
marked, 2u memory CD8 T cells. We found that similar fractions
of BALB/c and B6 2u memory CD8 T cells expressed Granzyme
B in response to dose-titrations of plate-bound anti-CD3e
(Figure 6E). Moreover, we observed equivalent IFN-c production
(% positive and MFI) by RAS-induced CD8a
loCD11a
hi 2u
memory CD8 T cells in BALB/c and B6 mice (data not shown).
Interestingly, however, a significantly higher fraction of B6 2u
memory CD8 T cells co-expressed TNF-a and IFN-c relative to
BALB/c 2u memory CD8 T cells, the majority of which expressed
IFN-c alone (Figure 6G). Collectively, these data show that a
TEM phenotype, but neither Granzyme B nor polyfunctional
cytokine expression, correlates with protective anti-Plasmodial liver
stage immunity mediated by RAS-induced memory CD8 T cells.
Extreme numerical requirements for CD8 T cell-mediated
protective immunity to sporozoite challenge
We previously reported that the numerical threshold for
protection of BALB/c mice against Pb-sporozoite challenge
mediated solely by memory CS252–260-specific CD8 T cells is
exceedingly high (.1% of PBL (refs [16,42]), or .8% of CD8 T
cells, Figure 7). One explanation for the enormously high
threshold for sterilizing protection in that scenario is that
protective memory CD8 T cells recognize only a single antigenic
determinant from P. berghei. On the other hand, RAS-vaccination
has been shown to elicit protective CD8 T cells targeting non-CS
antigens [14,15] and our data are consistent with the majority of
RAS-induced CD8 T cells targeting non-CS antigens (Figure 1B
and Figure S3). Thus, broadening the number of antigens (i.e.
additional parasite-derived proteins that may be more efficiently
processed or presented compared to CS) through whole parasite
RAS-vaccination may lower the numerical requirements for
protective immunity mediated by memory CD8 T cells. However,
when we tabulated memory CD8 T cell responses in groups of
RAS-vaccinated inbred and outbred mice that resisted sporozoite
challenge, we identified similarly extreme numerical relationships
between circulating memory CD8 T cell responses and protective
anti-sporozoite immunity (Table 1). This is most evident for RAS-
induced protective immunity against P. yoelii, which replicates
faster in the liver [43] and exhibits a lower ID50 [32] compared to
Figure 7. Sterilizing anti-P. berghei sporozoite immunity in BALB/c mice is associated with memory CD8 T cell responses of single
antigenic-specificity that exceed 8% of all circulating CD8 T cells. BALB/c mice were DC-CS252–260 prime, LM-CS252–260 boost immunized as
previously described [16]. Eighty-six days following immunization, peripheral blood from individual mice was assayed for the frequency of CS252–260-
specific memory CD8 T cells using intracellular IFN-c cytokine staining. Mice are ranked according to the magnitude of the CS252–260-specific memory
CD8 T cell response. Three days after T cell analyses, mice were challenged with 1000 Pb sporozoites and blood stage parasitemia was evaluated in
individual mice with Giemsa stain. Non-protected mice are indicated with filled circles. Numbers above the graph refer to percent protection among
mice scoring above or below the 8% circulating CS252–260-specific memory CD8 T cell threshold, which is based on the clearest visual break-point
between non-protected and protected mice each ranked according to the magnitude of the CD8 T cell response. Ninety-one percent (20/22) of age-
matched, naı ¨ve BALB/c mice challenged in parallel were parasitized.
doi:10.1371/journal.ppat.1000998.g007
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in humans. For example, anti-Py memory CD8 T cell responses
representing ,9% of CD8 T cells in BALB/c mice and ,19% of
CD8 T cells in Swiss Webster mice confer protection against a Py-
sporozoite challenge, and responses exceeding 40% of CD8 T cells
failed to efficiently protect B6 mice. Thus, the numerical
requirements for sterilizing immunity following Plasmodium RAS-
vaccination are extraordinarily high, regardless of whether the
protective pool of memory CD8 T cells react to a single antigenic
determinant after subunit vaccination, or whether the CD8 T cell
response is directed against a broader set of antigenic determinants
after whole-parasite immunization.
Discussion
Although a critical protective role for CD8 T cells in RAS-
immune mice was established more than 25 years ago, the
characteristics of the protective CD8 T cell response remained
essentially undefined due to the lack of defined Plasmodium
epitopes. Here, we used surrogate activation markers to identify
and longitudinally track RAS-induced CD8 T cell populations in
the blood of individual hosts. This approach enabled us to describe
specific quantitative and qualitative characteristics of memory
CD8 T cell populations that mediate protection against sporozoite
challenge. Moreover, the surrogate activation marker approach
allowed us to monitor RAS vaccine-induced CD8 T cell responses
in individuals within outbred populations of mice, without a priori
knowledge of MHC alleles or parasite-specific antigenic determi-
nants. These latter analyses revealed that, despite variability to the
initial immunization, prime-boost RAS-vaccination effectively
enhances parasite-specific memory CD8 T cell responses and
affords sterilizing protective immunity among individuals of an
outbred population. Collectively our studies show that indepen-
dent of genetic background, extremely high frequencies of RAS-
induced memory CD8 T cells are required, but may not always
suffice for sterilizing anti-Plasmodial immunity, information directly
relevant to ongoing efforts to translate attenuated whole-malaria
parasite vaccines to humans.
We previously reported that an extraordinarily large frequency
of circulating CS-specific memory CD8 T cells generated by
subunit vaccination is required to protect BALB/c mice against a
stringent Pb sporozoite challenge [16]. In that study, memory CD8
T cell populations were generated such that they only targeted a
single antigenic determinant derived from the parasite CS protein,
CS252–260. Herein we report the striking observation that
diversifying the targets of the CD8 T cell response through
whole-attenuated-parasite vaccination only minimally (if at all)
reduces the numerical requirements for memory CD8 T cell-
mediated protective immunity. For example, we show that
following Pb-RAS vaccination of BALB/c mice (the scenario in
which protection is easiest to achieve) resistance to sporozoite
challenge at a memory time point is associated with $4% of the
CD8 T cell compartment exhibiting the antigen-experienced
phenotype (CD8a
loCD11a
hi). Thus, the magnitude of the RAS-
induced, poly-specific memory CD8 T cell response associated
with protection against P. berghei challenge is only ,2-fold lower
than the mono- (CS252–260)-specific memory CD8 T cell response
(,8% of the CD8 T cell compartment). Additionally, protection
against Pb is associated with even larger memory CD8 T cell
responses in B6 and outbred Swiss Webster mice (11% and 12%,
respectively). Further, resistance to P. yoelii has even more extreme
requirements, with protection associated with RAS-induced
memory CD8 T cell responses exceeding ,9o r,19% of the
CD8 T cell compartment in BALB/c and Swiss Webster mice,
respectively. Thus, our data demonstrate that poly-specific
memory CD8 T cell-mediated sterilizing immunity to sporozoite
challenge, regardless of the relative virulence of the Plasmodium
species, requires commitment of a substantial fraction of the entire
CD8 T cell compartment.
This extreme numerical requirement is perhaps not surprising
given the extraordinarily low ratio of Plasmodium-infected cells to
total hepatocytes in the mammalian host following challenge with
physiological numbers of sporozoites (,1000). Indeed, the gold
standard readout for protection against sporozoite challenge is
sterilizing immunity, or the prevention of blood stage infection.
From a conservative perspective, this level of protection requires
that each of a maximum of 1000 infected hepatocytes (among
.10
8 or .10
11 total hepatocytes in the mouse or human liver,
respectively) be targeted through direct CTL activity or indirectly
via the release of cytokines by parasite-specific memory CD8 T
cells in order to prevent the development of blood stage infection.
Thus, each RAS-induced memory CD8 T cell must surveil an
extremely large number of hepatocytes in order to identify all cells
that harbor parasites. The exceedingly low number of infected
cells among the whole liver (needle in the haystack [16]), coupled
with the fact that every single infected cell must be successfully
targeted to prevent blood stage infection, is the likely explanation
for why the numerical requirements for memory CD8 T cell-
mediated, anti-Plasmodial liver stage immunity are so high.
While it is unclear why commitment of nearly 40% of the CD8
T cell compartment to the anti-Plasmodial memory CD8 T cell
response is insufficient to effectively protect B6 mice, our studies
extend the literature [11,20] by showing that host genetics play a
significant role in determining the outcome of sporozoite challenge
following RAS-vaccination at bona fide memory time points. We
were unable to detect CS-specific CD8 T cell responses in RAS-
vaccinated B6 mice (data not shown), which could account for
reduced protection. However, experiments have consistently
shown that RAS-immune B10.D2 mice are equally as difficult to
protect as B6 and B10 mice [11,20]. Importantly, B10.D2 mice
express the same MHC genes as BALB/c mice and thus are able
to mount CD8 T cell responses against the defined CS epitopes.
Thus, vaccine-induced CD8 T cell responses against the defined
immunodominant CS determinant are not sufficient for protec-
tion, underscoring the role of non-MHC-linked genes in regulating
RAS-induced, anti-liver stage immunity.
Another hypothesis to explain the dramatic susceptibility of
hyper-Py-RAS-immune B6 mice is that critical phenotypic or
Table 1. Extreme commitment of the CD8 T cell
compartment is associated with protection against
Plasmodium sporozoite challenge.
BALB/c C57BL/6 Swiss Webster
P. berghei 4.260.53%
a,b (n=25)
c 1161.0% (n=15)
d 1262.8% (n=23)
e
P. yoelii 8.861.2% (n=15)
d N.I.
f 1964.5% (n=17)
e
aNumbers are percent (6S.E.M.) of circulating CD8 T cells that exhibit an
antigen-experienced phenotype (CD8a
loCD11a
hi) in RAS-vaccinated mice that
resisted homologous challenge with 1000 P. berghei or P. yoelii sporozoites.
bRAS-induced responses were calculated after subtracting the CD8a
loCD11a
hi
responses of individual naı ¨ve mice measured prior to RAS-immunization.
cSingle-vaccinated mice (1 dose of 2610
4 Pb-o rPy-RAS).
dDouble-vaccinated mice (2 doses of 2610
4 Pb-o rPy-RAS).
eDouble and triple-vaccinated mice (2 or 3 doses of 2610
4 Pb-o rPy-RAS).
fN.I.=Not Included. Only groups of mice exhibiting .80% protection after 1, 2
or 3 RAS-vaccinations were included in this analysis.
doi:10.1371/journal.ppat.1000998.t001
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differ in B6 and BALB/c, regulate protective liver stage immunity.
Although we found no differences in granzyme B, IFN-c, TNF-a
or IL-2 production by BALB/c- compared to B6-derived, RAS-
induced memory CD8 T cells we did observe differential
expression of key molecules that differentiate TCM from TEM
populations. RAS-induced memory CD8 T cell populations
in B6 mice consistently exhibited elevated proportions of
CD62L
hiCD27
hi populations (TCM phenotype) compared to the
predominantly TEM populations found in BALB/c and Swiss
Webster mice. These data demonstrate a clear correlation between
the expression of the TEM (CD27
loCD62L
lo) phenotype of
secondary memory CD8 T cells and the ability of RAS-immune
BALB/c and Swiss Webster mice to resist sporozoite challenge.
The reason(s) for the difference in memory phenotype between
RAS-immune B6 and BALB/c or/Swiss Webster mice are
unknown. Interestingly, a recent report using a sensitive in vivo
assay suggests that CS antigen persists for long periods of time
after RAS immunization [44]. These studies were carried out only
in BALB/c mice due to reagent availability. Given the potential of
prolonged antigen encounter to influence memory T cell
phenotype, it will be of interest to determine if antigen fails to
persist in B6 mice and accounts for the altered T cell phenotype
and reduced protection after RAS-immunization. Finally, it should
be noted that, due to the enormous numbers of memory CD8 T
cells required for sterilizing immunity, adoptive transfer studies to
compare the per cell protective capacity of CD8a
loCD11a
hi
memory populations from RAS-immune BALB/c and B6 have
not succeeded Although it may be possible to measure reductions
in parasite liver burden in CD8 T cell-recipient mice using
quantitative PCR, this generally requires challenging mice with
supraphysiological doses of sporozoites, a scenario that we wished
to avoid. In addition, our interests are focused on the properties of
memory CD8 T cells that result in sterilizing immunity and it is
currently unclear how reduction in parasite burden after high dose
challenge models complete elimination of infected hepatocytes.
Clearly many other characteristics of the RAS-induced memory
CD8 T cell response may contribute to protective immunity and
warrant further investigation. Importantly, our surrogate activa-
tion marker approach should allow for detailed, prospective
characterization of RAS-induced memory CD8 T cell responses in
individual hosts, so that potential links between specific memory
CD8 T cell attributes and protection can be evaluated. The
identification of additional factors that correlate with or determine
CD8 T cell-mediated protective immunity following RAS-
vaccination should provide key insight into the pathways of
protective CD8 T cell-mediated immunity elicited through whole-
parasite vaccination.
Our data highlight the utility of the surrogate activation marker
approach for understanding Plasmodium-induced CD8 T cell
responses in genetically diverse populations by providing a
framework with which the field can begin to address several
additional critical knowledge gaps. First, use of outbred rodents to
evaluate vaccine-induced responsiveness and protective immunity
is much more likely to mimic responses in genetically diverse
humans or non-human primates. Identifying and characterizing
individual-to-individual variability in response to vaccination
should provide additional critical information that will comple-
ment data obtained through studying the highly overlapping
responses in genetically identical, inbred rodent populations.
Second, our studies provide a framework with which to optimize
whole parasite immunization. Identifying ways to enhance
potentially suboptimal delivery routes, vaccine doses or schedules,
based on a quantitative and qualitative assessment of the total
CD8 T cell response, will significantly improve efforts to optimize
RAS-vaccination, or any other candidate vaccine delivery
approaches. Lastly, the surrogate activation marker approach
now permits direct comparisons between RAS and the genetically
attenuated parasite (GAP) vaccines. Recent work has shown that
such genetically attenuated Plasmodium parasites, harboring defined
mutations in one or more key genes required for full liver stage
differentiation, afford CD8 T cell-dependent protective immunity
in rodents [33,45]. Moreover, it has been shown that the targeted
gene(s) precisely control the point during liver stage development
that the GAP arrests [31,45,46,47]. Whether early arresting or late
arresting GAP-vaccine candidates differentially impact the pro-
tective characteristics of the CD8 T cell response is unknown.
Given the potential safety advantage of GAP vaccination, these
will be critically important questions that can now be directly
addressed using surrogate activation markers to identify vaccina-
tion-induced effector and memory CD8 T cell responses.
Materials and Methods
Ethics statement
All animal studies and procedures were approved by the
University of Iowa Animal Care and Use Committee, under PHS
assurance, Office of Laboratory Animal Welfare guidelines.
Mice
Specific pathogen-free BALB/c, C57BL/6, and Swiss Webster
mice were purchased from the National Cancer Institute (NCI)
and housed at the University of Iowa animal care unit at the
appropriate biosafety level.
Parasites
Female Anopheles stephensi mosquitoes infected with either P.
berghei (NK65) or P. yoelii (17XNL) were purchased from the New
York University insectary.
Immunizations
P. berghei and P. yoelii sporozoites were isolated from the salivary
glands of infected A. stephensi mosquitoes. Sporozoites were
attenuated by exposure to 200 Gy (20,000 rads). Mice were
immunized with 200 to 100,000 RAS i.v. Boosted mice received
20,000 RAS no less than 60 days apart. In some experiments mice
were injected with 60 mg/kg primaquine (Sigma-Aldrich, St.
Louis, MO) i.p. on days 5 and 6 following RAS immunization.
Subunit immunizations were performed as previously described
[16]. Briefly, BALB/c mice were primed via tail vein injection of
1610
6 splenic dendritic cells coated with peptides corresponding
to CS252–260 of P. berghei (DC-CS252–260). Seven days later, mice
were boosted with 2610
7 CFU of recombinant Listeria monocytogenes
expressing the CS252–260 determinant as a secreted minigene (LM-
CS252–260).
Sporozoite challenges
P. berghei and P. yoelii sporozoites were isolated from the salivary
glands of infected A. stephensi mosquitoes. Immunized and naı ¨ve
age-matched mice were challenged with 1000 sporozoites i.v. Thin
blood smears were performed 10 days after sporozoite challenge.
Parasitized red blood cells were identified by Giemsa stain and oil-
immersion (10006) light microscopy. Protection is defined as the
absence of blood stage parasites. At least 10 fields (,10–15,000
red blood cells) were examined for each mouse designated as
protected. Protected mice were subsequently rechallenged follow-
ing T cell depletion to verify that protection was CD8 T cell-
dependent.
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CD8 T cells
RAS vaccine-induced CD8 T cell populations were identified
by staining spleen or liver single cell suspensions, or peripheral
blood following lysis of red blood cells, with anti-CD8a clone 53–
6.7 (eBioscence, San Diego, CA) and anti-CD11a (LFA-1a) clone
M17/4 (eBioscience) antibodies. Sporozoite-specific CD8 T cells
were phenotyped by staining cells with anti-CD27 clone LG.7F9,
anti-CD43 clone 1B11, anti CD62L clone MEL-14, anti-CD127
clone A7R34, anti-CD25 clone PC61, anti-CD69 clone H1.2F3,
anti-CD44 clone IM7, anti-CD122 clone 5H4 antibodies, all from
eBioscience. In some experiments, 8610
4 Py-RAS-induced
primary memory cells from CD90.2
+ BALB/c or CD45.2
+ B6
mice were adoptively transferred to naı ¨ve, congenic (CD90.1
+ or
CD45.1
+) recipients. One day following transfer, recipients were
boosted with 1610
5 Py-RAS. Thirty-three days later, splenocytes
were stimulated ex vivo in anti-CD3e-coated wells. BALB/c and B6
donor cells were identified by CD11a
hiCD8a
loCD90.2
+ or
CD11a
hiCD8a
loCD45.2
+ surface staining and further character-
ized by intracellular staining for IFN-c, TNF-a and IL-2, or
Granzyme B. CS252–260- and CS280–288-specific CD8 T cells were
identified by incubating peripheral blood leukocytes with K
d/
CS252–260-APC labeled tetramers or K
d/CS280–288-APC labeled
tetramers, respectively. Cells were then stained with anti-CD8a,
anti-CD90.2 and anti-CD11a. Following subunit immunization,
the frequency of circulating CS252–260-specific CD8 T cells was
determined by ex vivo intracellular cytokine staining for IFN-c
following a 5.5 hour incubation with brefeldin A in the presence or
absence of CS252–260 peptide-coated P815 cells were used as
antigen presenting cells. Cells were analyzed using a BD
FACSCanto and data was analyzed using FLOWJO Software
(Tree Star, Inc, Ashland, OR). All animals were pre-bled prior to
RAS vaccination to establish individual background circulating
CD8a
loCD11a
hi T cell frequencies.
T cell depletions
Immunized mice were injected with 0.4 mg i.p. rat IgG, anti-
CD4 (clone GK1.5), or anti-CD8 (clone 2.43) antibodies on day
23 and day 21 prior to challenge with sporozoites. Depletion was
verified by analyzing CD4 (clone RM4-5) and CD8 (clone 53-6.7)
T cell populations in the blood of individual mice prior to
challenge. In each case, the relevant population represented
,0.5% of the PBL.
Sporozoite-specific antibody titer
The serum sporozoite-specific antibody titer from immunized
mice was determined by the indirect fluorescent antibody test
(IFAT). Sporozoites were air dried on a multiwell microscope slide
(Cel-Line Thermo Scientific) and blocked with 1% BSA/PBS.
Sporozoite-specific IgG antibodies were detected by incubating
with Cy3-conjugated goat anti-mouse IgG (Jackson Immunor-
esearch Laboratories). Titers are expressed as the inverse of the
lowest dilution of serum that retained immunoreactivity against
air-dried sporozoites.
Supporting Information
Figure S1 CD8a
loCD11a
hi memory cells, but not naive
CD8a
hiCD11a
lo cells, sorted from Py-RAS-immune mice specif-
ically expand in naive recipient hosts following Py-RAS vaccina-
tion. Splenic memory CD8a
loCD11a
hi and naive CD8 T cells
were simultaneously sorted from (CD45.2
+) B6 donor mice 78
days following immunization with 2610
4 Py-RAS. 2610
5 sort-
purified memory or naive cells were transferred to naive (CD45.1
+)
recipient B6 mice one day before immunization with 1610
5 Py-
RAS. The frequency of circulating donor-derived (CD45.2
+) CD8
T cells in each recipient mouse was monitored starting on day 4
post-immunization.
Found at: doi:10.1371/journal.ppat.1000998.s001 (0.44 MB EPS)
Figure S2 Depletion of CD8 T cells, but not CD4 T cells,
abrogates protection in Pb- and Py-RAS vaccinated C57BL/6 and
BALB/c mice, respectively. (A) Naı ¨ve C57BL/6 mice (N=20)
were vaccinated via tail vein with 2610
4 Pb-RAS. Eighty-six days
later, mice were boosted with 2610
4 Pb-RAS. Eighty-two days
following boost the frequency of CD8a
loCD11a
hi T cells in the
peripheral blood was evaluated and individual mice were ranked
according to the magnitude of the secondary memory CD8 T cell
response. Groups of mice, as indicated, were treated with 0.4 mg
rat IgG, anti-CD4 (GK1.5) or anti-CD8 (2.43) 3 days and 1 day
prior to challenge with 1000 Pb sporozoites. Complete CD8 or
CD4 T cell depletion was verified by collecting a small volume
(,20 mL) of peripheral blood from each individual mouse on the
day of sporozoite challenge followed by staining for both CD4
(RM4-5) and CD8 (53-6.7) (data not shown). Numbers above the
graph refer to the percent of T cell-depleted mice that remained
protected (no. protected/no. challenged6100) following Pb
sporozoite challenge. Blood stage parasitemia was evaluated by
Giemsa stain. (B) Similar to A, except CD8 T cell-dependent
protection was evaluated in BALB/c mice primed and boosted
with 2610
4 Py-RAS. In B, mice were challenged with 1000 Py
sporozoites following T cell depletions.
Found at: doi:10.1371/journal.ppat.1000998.s002 (0.47 MB EPS)
Figure S3 Homologous boosting with RAS enriches the
representation of CS252–260-o rC S 280–288-specific CD8 T cells
within the vaccine-induced CD8a
loCD11a
hi population. (A)
Representative dot plots showing the fraction of circulating CD8
T cells exhibiting an antigen-experienced phenotype (CD8a
loC-
D11a
hi) in a naı ¨ve mouse (top), memory Pb-RAS-immune (middle)
and Py-RAS-immune (bottom) mouse 7 days following homolo-
gous RAS boost. (B) Samples from memory mice (shown in A)
subgated into CD11a
hi and CD11a
lo populations and analyzed for
K
d/CS252–260 or K
d/CS280–288 tetramer staining. (C) Fraction of
CD11a
hi cells that are K
d/CS252–260 tetramer+ following primary
Pb-RAS vaccination (day 7) or one week following homologous Pb-
RAS boosting of memory mice (day 61+7). (D) Similar to C,
except Py-RAS immune mice were analyzed. For C and D, data
are mean 6 SD (n=3/group). Statistics were determined by
unpaired, two-tailed t-tests.
Found at: doi:10.1371/journal.ppat.1000998.s003 (0.81 MB EPS)
Figure S4 Anti-P. yoelii sporozoite serum IgG antibody titers are
not significantly different between protected and non-protected
mice following Py-RAS prime-boost vaccination. (A) Anti-Py
sporozoite IgG antibody titers in the serum of individual BALB/
c, C57BL/6 and Swiss Webster mice at secondary (2u) and tertiary
(3u) memory time-points were evaluated. Titers form individual
mice are shown. (B) Comparison of serum anti-sporozoite titers
among protected 2u memory BALB/c and non-protected 3u
C57BL/6 mice. (C) Anti-sporozoite titers were averaged among
the 6 protected or the 14 non-protected 2u and 3u memory B6
mice shown in Fig. 4F. Statistics were determined by unpaired,
two-tailed t-tests.
Found at: doi:10.1371/journal.ppat.1000998.s004 (0.49 MB EPS)
Figure S5 Cell surface phenotype of RAS-induced, secondary
memory CD8 T cells from BALB/c and B6 mice. Allelically
marked, secondary memory CD8 T cells in BALB/c and B6 mice
were generated as described in Materials and Methods. Briefly,
Plasmodium-Induced Total Memory CD8 T Cell Responses
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4 Py-RAS-induced, primary memory CD8a
loCD11a
hi T cells
from CD90.2
+ BALB/c or CD45.2
+ B6 mice were transferred to
CD90.1
+ or CD45.1
+ congenic recipients, respectively. One day
following transfer, recipient mice were vaccinated with 1610
5 Py-
RAS. Thirty-three days later, splenocytes were harvested and
stained with CD8a, CD11a and CD45.2 or CD90.2 to identify B6
or BALB/c secondary memory CD8 T cells, respectively. Aliquots
of cells were subsequently stained for expression the indicated
CD8 T cell activation or survival marker. Representative dot plot
and histograms are shown for a single BALB/c and B6 recipient
mouse. Numbers indicate the fraction of donor-derived, Py-RAS-
specific secondary memory CD8 T cells expressing the indicated
marker. Isotype control antibody staining for each activation or
survival marker is shown as a shaded histogram.
Found at: doi:10.1371/journal.ppat.1000998.s005 (1.60 MB EPS)
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